Medpace (MEDP)
(Delayed Data from NSDQ)
$356.40 USD
+13.51 (3.94%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$356.40 USD
+13.51 (3.94%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Zacks News
Medpace (MEDP) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 28.98% and 8.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 19.10% and 2.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 6.67% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Up 42% in a Year: More Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on a diversified healthcare treatment network resulting from growth-related efforts.
Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders
by Zacks Equity Research
Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the tactical deployment of capital.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny
by Zacks Equity Research
Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.
HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery
by Zacks Equity Research
HCA Healthcare's (HCA) ESR program remains on track to attract more patients to choose HCA's healthcare facilities for undergoing surgeries.
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.
HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments in the third quarter of fiscal 2023.
Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.
Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay
by Zacks Equity Research
Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.
Thermo Fisher (TMO) End Markets Grow Strong, Margin Woe Stays
by Zacks Equity Research
Thermo Fisher (TMO) witnesses strength in three of its four end markets, categorized either by customer type or geography.
Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.
Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both of its segments.
NextGen (NXGN) Buys TSI Healthcare to Boost Ambulatory Services
by Zacks Equity Research
NextGen (NXGN) acquires TSI Healthcare which may further solidify NXGN's position in the ambulatory healthcare space.
Patterson Companies (PDCO) Q2 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter 2023 results reflect unfavorable currency movements.
Molina Healthcare (MOH) Up 11% in 6 Months: More Room to Run?
by Zacks Equity Research
Molina Healthcare (MOH) is well-poised for growth on growing premiums, membership increases in Government business and sufficient cash reserves.
Factors That Make Elevance Health (ELV) a Lucrative Bet Now
by Zacks Equity Research
Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.
Humana (HUM) Issues $1.25B Senior Notes, To Lower Debt Level
by Zacks Equity Research
Humana (HUM) issues senior notes with the intent to procure funds to trim its escalating debt level.
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.
Zacks.com featured highlights include Conagra Brands, Medpace Holdings, BP, Avis Budget Group and Liberty Energy
by Zacks Equity Research
Conagra Brands, Medpace Holdings, BP, Avis Budget Group and Liberty Energy are part of Zacks Screen of the Week article.
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Stocks With Upgraded Broker Ratings to Fight Macro Challenges
by Swayta Shah
As brokers have more insight into stocks, one must follow rating upgrades before investing. We pick Conagra Brands (CAG), Medpace Holdings (MEDP), BP, Avis Budget Group (CAR) & Liberty Energy (LBRT), as these have seen rating upgrades.